We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HYNE:NASDAQHoyne Bancorp, Inc. Analysis

Data as of 2026-06-18 - not real-time

$16.62

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: HYNE is trading at its 52‑week high of $16.62, just above the 20‑day SMA ($16.13) and well above the 50‑day SMA ($15.90), indicating a short‑term bullish alignment. The 14‑day RSI is soaring at 79.6, signaling overbought conditions, while the MACD remains bullish though the histogram is thin. Fundamentals: The stock carries an astronomically high trailing PE of 415x versus an industry average of 17x, yet its price‑to‑book is below 1 (0.84), reflecting an apparent discount to book value. Revenue grew 13% YoY, but operating margins are negative and cash flow is weak, with a modest cash pile of $14.4 M against $1.4 M of debt.
Risk & valuation: Low beta (0.18) and modest 30‑day volatility (8.2%) suggest limited price swings, but the combination of extreme valuation multiples, thin profitability, and a highly concentrated regional‑bank exposure raises caution. The market’s “Extreme Greed” sentiment (FGI 88.5) may be inflating price momentum beyond fundamentals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Overbought RSI suggests limited upside in the near term
  • Price is at resistance with thin MACD histogram
  • Low beta and modest volatility support a neutral stance

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Potential pull‑back to support around $15.58 offers entry margin
  • Book‑value discount (P/B < 1) provides upside if earnings improve
  • Revenue growth of ~13% indicates underlying business momentum

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Persistent earnings weakness and negative operating cash flow
  • Strong balance sheet with low debt but limited profitability
  • Regional‑bank sector exposure to interest‑rate and regulatory shifts

Key Metrics & Analysis

Financial Health

Revenue Growth12.90%
Profit Margin1.76%
P/E Ratio415.5
ROE0.22%
ROA0.06%
P/B Ratio0.8
Op. Cash Flow$-481449
Industry P/E17.1

Technical Analysis

TrendBullish
RSI79.6
Support$15.58
Resistance$16.62
MA 20$16.13
MA 50$15.90
MA 200$14.91
MACDBullish
VolumeIncreasing
Fear & Greed Index88.5

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta0.18
Volatility8.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.